Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:53:13.154Z.
Calculation as of: 2026-10-06T21:53:13.154Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 08fea6a2878daf509c4a2714b7418dcfec0265989d531cb4479ebc608e1bd708
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$284.31M
EV/EBIT Ratio
N/A
TTM Avg
15.89x
3Y Avg
15.15x
5Y Avg
15.15x
Market Cap
$280.37M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$292.59M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$293.30M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sagimet Biosciences Inc. (SGMT) | $285.42M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $284.31M | N/A | 15.89x | 15.15x | 15.15x |
| Standard BioTools Inc. (LAB)vs › | $282.64M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $288.79M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $293.30M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | N/A | 27.51x | 26.71x | 33.46x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
